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• Secondary Malignant Histiocytosis (SMH) is an exceedingly rare, life-threatening condition that invariably
occurs in the presence of an underlying monoclonal hematologic disorder. Prognosis of SMH remains dismal
and there is no established treatment.
• We report a case of a patient who developed SMH during induction chemotherapy for his underlying pre-B-
ALL, that caused persistently high fevers and was only diagnosed by a marrow while cytopenic in phase 2
induction. He was treated with alemtuzumab-based therapy that reduced the histiocytic inﬁltration of the
bone marrow from 80% to 15% and made him eligible to undergo T-cell replete allogeneic stem trans-
plantation from his sibling.
• This report is the ﬁrst to highlight the role of alemtuzumab, an anti-CD52 monoclonal antibody, in clonal
disorders originating from transdiﬀerentiation.
• The alemtuzumab-based regimen should be reserved only for carefully selected allogeneic transplant pa-
tients.
1. Introduction
Secondary Malignant Histiocytosis (SMH) is a distinct entity and
forms part of a spectrum of disorders of the monocyte-phagocytic
lineage, categorised into ﬁve main groups in the current WHO classi-
ﬁcation. It includes conditions such as Langerhans Cell Histiocytosis
(LCH), Hemophagocytic Lymphohistiocytosis (HLH), Rosai-Dorfman
disease, cutaneous and mucocutaneous manifestations of these dis-
orders and primary and secondary malignant histiocytosis [1–3]. It can
occur either as a sporadic illness or secondary to clonally-related he-
matological malignancies. Pathogenesis of SMH remains unclear but it
is derived from cells of the Macrophage/Dendritic Cell (DC) system and
is most commonly associated with Acute Lymphoblastic Leukemia
(ALL) and Follicular Lymphomas, as well as myeloid disorders like
Chronic Myelomonocytic Leukemia (CMML) and Acute Myeloid Leu-
kemia (AML). SMH is diagnosed based on anaplastic morphology,
expression of macrophage and DC markers, a deﬁnite temporal and a
probable clonal relationship with the primary hematologic neoplasm
[1]. The marked hyperferritinemia, triglyceridemia and hemophago-
cytosis in the bone marrow, typical of HLH, are generally not seen in
SMH.
2. Case report
A 40-year-old male, with no past medical history of signiﬁcance
other than smoking, attended the general practitioner's clinic with three
weeks’ history of feeling generally unwell and one-week history of night
sweats. At presentation, the patient did not manifest any signs or
symptoms of marrow failure. He also did not have pallor, jaundice,
lymphadenopathy, or hepatosplenomegaly. Initial full blood count
(FBC) showed a hemoglobin of 14.4 g/dL, platelets of 59 × 109/L,
white cell count of 38.8 × 109/L and neutrophils of 4.11 × 109/L.
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Liver function tests, lactate dehydrogenase (LDH), creatinine, electro-
lytes and coagulation screen were normal. A peripheral blood ﬁlm re-
vealed lymphoblasts.
Bone marrow aspirate and trephine showed a hypercellular marrow
with decreased tri-lineage hematopoiesis and 90% blasts [Fig. 1(a)].
Flow cytometry conﬁrmed Pre-B-Cell Acute Lymphoblastic Leukemia
(Pre-B-ALL) and karyotyping met the criteria for complex cytogenetics
[4]. Molecular analyses were negative for a bcr-abl1 transcript (both
p190 and p210 variants).
The patient was enrolled in the UKALL14 trial (09/H0711/90) in
May 2016 and was randomized to receive 4 doses of rituximab in phase-
1 induction. Bone marrow assessment after phase-1 of 4-drug induction
chemotherapy revealed the persistence of 13% blasts by ﬂow cytometry
and 15% on trephine [Fig. 1(b)]. As per protocol, it was decided that he
should continue with phase-2 of induction therapy (cyclophosphamide,
cytosine arabinoside and 6-mercaptopurine). He then developed per-
sistently high fevers and was treated with broad-spectrum antibiotics
for neutropenic fever. Anti-viral and anti-fungal prophylaxis was con-
tinued during this time. Microbiological investigations for viral, fungal
and bacterial pathogens were repeatedly negative. Imaging studies in-
cluding a CT and PET scans did not show lymphadenopathy, hepatos-
plenomegaly, or other organ involvement. In view of his persistent
fever, a mid-cycle bone marrow aspirate and trephine were performed
which showed a reduction in lymphoblasts to 5% by ﬂow cytometry
and an extensive inﬁltration of malignant histiocytes, amounting to
nearly 80%, with no associated hemophagocytosis [Figs. 2(a) & (b);
3(a) & (b)]. This ‘secondary malignant histiocytosis’ (SMH) was con-
sidered to be the cause of his persistent fevers, based on ﬂow cytometric
analysis. Karyotyping was not performed on the marrow at this stage.
There was mild hepatomegaly, no splenomegaly, ferritin levels were
1197 microgram/L (normal 10–400 mcg/L), whereas LDH and trigly-
ceride levels were normal. Other diﬀerential diagnoses which were
ruled out included: Anaplastic large cell lymphoma (negative staining
for CD30 and ALK1), carcinoma (negative staining for cytokeratin) and
dendritic cell neoplasms (negative staining for CD23 and S100 as well
as morphology). Phase-2 induction chemotherapy was discontinued.
His secondary malignant histiocytosis was treated with alemtu-
zumab (Campath) 2.4 mg/kg over 5 days [5], intravenous
immunoglobulins (IVIG) 1 gm/kg for 2 days and methylprednisolone
2 mg/kg for 5 days. He defervesce after 48 h and became well and
ambulant. Assessment of bone marrow on day 15, 2 weeks after re-
ceiving alemtuzumab, showed a decrease in histiocytes to less than 15%
and lymphoblasts to 0.1% by ﬂow cytometry.
With an excellent performance status, normalization of blood counts
and a partial response of his SMH, it was decided to proceed to T-cell
replete allogeneic stem transplantation from his sibling with ﬂudar-
abine (40 mg/m2/day) on days − 7 to − 3 and IV busulfan (130 mg/
m2/day) conditioning on days − 6 to − 3 [6]. His bone marrow ex-
amination, 70 days’ post-allogeneic stem cell transplantation, showed a
complete morphological [Fig. 4], ﬂow cytometric and cytogenetic re-
mission. He developed features of mild skin graft versus host disease
(GVHD), 2 months’ post-transplant, which was treated with topical
steroids. The patient maintained complete remission for 8 months’ post-
allogeneic stem cell transplant but has relapsed with ALL in thigh
muscles, the middle ear and the leptomeninges. Biopsies from two sites
reveal no evidence of SMH.
3. Discussion
Histiocytoses encompass a rare, heterogeneous group of disorders
characterized by the aggregation of cells of mononuclear-phagocytic
lineage and occur more commonly in children. Histiocytes, a morpho-
logical term for tissue-dweller macrophages, perform the phagocytic
function whereas dendritic cells (DC) are involved in antigen pre-
sentation and T-cell activation. Nomenclature for this rare entity has
evolved since 1987 and most recent classiﬁcation group >100 subtypes
into 5 categories [1,2].
Secondary Malignant Histiocytosis (SMH) is a neoplastic disorder
occurring simultaneously or after another hematologic malignancy and
is classiﬁed under “M group (MH: Malignant Histiocytoses)” according
to the revised classiﬁcation of histiocytic disorders. SMH is diagnosed
based on anaplastic morphology, expression of macrophage and DC
markers, a deﬁnite temporal and a probable clonal relationship with the
primary hematologic neoplasm [2,3].
Diﬀerential diagnosis mainly includes high-grade lymphoma,
Fig. 1. (a): Bone Marrow Aspirate (H&E X 100) shows the presence of lymphoblasts
(arrows), consistent with ALL. (b): Bone Marrow Trephine (H&E X 100) shows the per-
sistence of lymphoblasts, highlighted with TDT staining (arrow), post-induction che-
motherapy Fig. 2. (a & b): Bone Marrow Trephine shows pleomorphic histiocytes (arrows), con-
sistent with Secondary Malignant Histiocytosis
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metastatic carcinoma, malignant melanoma, primary malignant his-
tiocytosis and requires the establishment of anaplastic morphology and
staining markers of macrophages/DCs, without synchronous hemato-
logical malignancy, via negative staining pattern and hence the exclu-
sion of other tumors.
SMH evolves through transdiﬀerentiation, a series of processes
where one diﬀerentiated somatic cell line transforms into another,
without going through a pluripotent cell phase [7]. Recent studies have
highlighted the important role transcription factors play in the trans-
diﬀerentiation of somatic and malignant cell lines, to specialized and
pluripotent stem cells, as well as across diﬀerent hematopoietic
lineages. Transcription factor C/EBPα, in particular, appears to play an
important role in relation to the pre-B cell to macrophage transdiﬀer-
entiation [8,9].
We report a case of SMH developing synchronously with pre-B ALL
in a 40-year-old male. There is no standard of care treatment for SMH
currently and prognosis remains poor, especially in patients with mul-
tisystem involvement. Data regarding treatment is derived from other
related histiocytic disorders, commonly HLH, and includes etoposide-
based combination chemotherapy [1–3]. There are reports in the lit-
erature of the use of Alemtuzumab in LCH and HLH [5,10] but seldom
for its use in the treatment regimens for SMH, likely because of the
rarity of SMH itself. Albeit malignant histiocytes were not examined for
CD52 expression in this case, evidence from response of other biolo-
gically and clinically similar conditions to alemtuzumab was extra-
polated and led to the clinical decision of utilizing this monoclonal
antibody in the setting of SMH and this patient responded well to
alemtuzumab, intravenous immunoglobulin and methylprednisolone.
4. Conclusion
This report is the ﬁrst to highlight the role of alemtuzumab, an anti-
CD52 monoclonal antibody, in clonal disorders originating from
transdiﬀerentiation. However, the alemtuzumab-based regimen should
be reserved only for carefully selected allogeneic transplant patients,
given its considerably long lympholytic half-life and established roles in
T-cell depletion and GVHD. Further studies are needed to better un-
derstand the transdiﬀerentiation phenomenon involved in SMH so that
speciﬁc molecular targets can be identiﬁed in order to improve the
dismal outlook associated with SMH.
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